Dec 17, 2004 by Brian GormanSepracor's Dream Drug?Investors should be awake to Lunesta's potential pitfalls.
Dec 16, 2004 by Brian GormanHarperCollins' State of BlissThe News Corp. publishing division appears to have a winning title on its hands.
Dec 15, 2004 by Brian GormanWyeth Keeps ProducingThe drug maker's difficulties are evident, but its productivity may make it worth a second look.
Dec 15, 2004 by Brian GormanKorea's Biotech BetKorea's new facility could stimulate biotech research in Asia and lower costs for biotech companies.
Dec 14, 2004 by Brian GormanBristol-Myers' Smart MovesAlthough problems still hang over the company, Bristol-Myers is paving the way for recovery.
Dec 14, 2004 by Brian GormanGeneral Mills' Latest TrixThe packaged food outfit is taking some important steps that should contribute to improved results down the road.
Dec 13, 2004 by Brian GormanWhich Medications Are Your Best Bets?Consumer Reports' effort to rate drugs offers a lesson to pharmaceutical companies.
Dec 13, 2004 by Brian GormanGM, Daimler Go GreenTeam-up will help the companies compete and fill gaps in both firms' portfolios.
Dec 10, 2004 by Brian GormanCardinal Picks a LillyCardinal Health's deal with Lilly suggests the new fee-for-service model is gaining traction.
Dec 9, 2004 by Brian GormanGlobal Growth Key to Beer WarsAnheuser-Busch teams up with Vietnam's largest brewer, laying the groundwork for future growth in the region.
Dec 8, 2004 by Brian GormanGlobal Hawk Costs SoarCost overruns won't endanger Northrop Grumman's latest surveillance aircraft program, but federal budget cuts will likely hamper future defense contracts.
Dec 7, 2004 by Brian GormanID Biomedical's Shot in the ArmID Biomedical appears well-positioned for the coming years, but it may be best to stay cautious on the company.
Dec 6, 2004 by Brian GormanPill-Popping NationAmericans are using more prescription drugs, but pharmaceutical companies can't take huge comfort in that.
Dec 3, 2004 by Brian GormanNYT's News Not Fit to PrintNew York Times' unwillingness to provide yearly guidance is a troubling sign.
Dec 2, 2004 by Brian GormanAre Tobacco's Days Numbered?A new global treaty on tobacco is sure to be trouble for tobacco companies.
Dec 1, 2004 by Brian GormanRational ExuberanceNektar received a positive boost from Pfizer's announcement that it will seek approval for Exubera.
Nov 30, 2004 by Brian GormanGlaxo Targeted for Kids' TrialsCriticism of Glaxo could benefit investors in the long run.
Nov 29, 2004 by Brian GormanGlass Half Full for BayerBayer is battling drug recall demons, but the company's positives seem to outweigh its negatives.
Nov 24, 2004 by Brian GormanToyota Under Porsche's Hood?Toyota may provide hybrid technology for Porsche.
Nov 23, 2004 by Brian GormanAstraZeneca Buys Into Cambridge AntibodyCambridge Antibody scored a new alliance, although the deal threatens to make it a house divided.
